Barmumycin was isolated from an extract of the marine actinomycete Streptomyces sp.
Introduction
Natural products from terrestrial plants and microorganisms have long been a traditional source of drugs; however, over the past few years, marine organisms have garnered everincreasing attention as a rich bank of new bioactive compounds. 1 Marine actinomycetes have also proven to be an important source of biologically active compounds.
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Among the marine actinomycetes that our group has studied, those of the genus
Streptomyces have clearly shown most pharmacological potential; however, in many bioactive cultures they have yielded only compounds that are already known. During ongoing research efforts to explore the biosynthetic potential of rare marine microorganisms, we isolated two known compounds pretomaymycin 3 and oxotomaymycin 4 ( Figure 1 ) plus the previously unknown compound barmumycin from the culture broth of the marine actinomycete Streptomyces sp. BOSC-022A, isolated from a tunicate collected off the Scottish coast.
Barmumycin and its diacetate show antitumor activity at micromolar concentrations in all 12
cancer cell lines tested (see Table 1 in the Supporting Information). Herein we report the isolation, total synthesis and structure elucidation of barmumycin. 
Results and Discussion
The molecular formula of barmumycin was determined to be C 15 The functionalized five-carbon chain on the aniline nitrogen was introduced by two different ways: via reductive amination (Scheme 2) and via N-alkylation (Scheme 3).
Homoallylic alcohol 2 was obtained by Barbier reaction of 2,2-dimethoxyacetaldehyde with allyl bromide and indium powder in water (95% yield). 7 protected using (CF 3 CO) 2 O in pyridine to afford the trifluoroacetamide derivative 6d in quantitative yield. Treatment of 6d with 10% TFA in CH 2 Cl 2 to remove the carbonate gave the free alcohol 6e in quantitative yield. Compound 6e was then oxidized with Dess Martin periodinate (DMP) 15 to yield the ketone 7 in 93% yield. Slow addition of 7 to Nmethylmorpholine oxide (NMO) and a catalytic amount of OsO 4 in acetone-H 2 O, to generate the corresponding diol 8 while preventing double bond isomerization gave 8 in good yield.
Diol 8 was further protected by conversion into its 2,2-dimethyl-1,3-dioxolane derivative 9, using 2,2-dimethoxypropane plus pyridinium p-toluenesulfonate (PPTS) as catalyst (quantitative yield). Deprotection of the amine in 9 via mild basic hydrolysis gave the free amine 10 in 97% yield.
A faster and better-yielding synthesis of 10 (Scheme 3) was done in parallel to the route described above. The first step was dihydroxylation of iso-butyl but-3-enoate. The introduction of the bromomethyl residue was planned for a later step. The oxidation conditions described above afforded iso-butyl 3,4-dihydroxybutanoate (11), which was then further protected as the 2,2-dimethyl-1,3-dioxolane derivative 12, in excellent overall yield for both steps. The key step, transformation of 12 into the bromoketone 13 using bromomethyllithium, gave 13 in 49% yield. N-Alkylation of 5 with 13 under microwave irradiation gave 10. 
16
Z/E-14 was transformed into 1 in three successive reactions: hydrolysis of the methyl ester; acetonide deprotection under acidic conditions; and macrocyclization. The acid Z-15 was obtained by purification of the Z/E mixture of acids by semipreparative HPLC.
17
Racemic Z-1 was obtained in 35% yield by acetal deprotection followed by macrocyclisation using EDC·HCl and solid-supported DMAP in a 5 mM CH 2 Cl 2 solution.
The 1 H-NMR spectrum of Z-1 showed two doublets for the CH 3 linked to the double bond (1.42 ppm and 1.45 ppm) and two quadruplets for the vinylic proton (5.51 and 5.53 ppm).
18
These data could be explained by the presence of two highly populated conformations of Z-1 at room temperature. Therefore, we studied peak coalescence by 1 H-NMR run at different temperatures. Spectra from the initial experiments, run up to 55 ºC in CDCl 3 as solvent, exhibited this trend, but coalescence was not reached at this temperature limit. Finally, coalescence was almost reached in DMSO-d 6 as solvent at 145 ºC (see Table 4 in the Supporting Information). Moreover, comparison of spectroscopic data for barmumycin with those for Z-1 revealed dramatic differences in the chemical shifts (see Tables 2 and 3 in the Supporting Information). This discrepancy, although the conflicting stereochemistry of the two compounds (Z-1 and E-barmumycin), led us to pursue a new structural assignment.
Re-evaluation of all possible alternative structures led us to systematic elucidation of E-16 as a novel structure for barmumycin ( Figure 3) . Interestingly, the very close structural resemblance of 16 to the pretomaymycin and oxotomaymycin isolated from the extract ( Figure 1 ) suggests that all three molecules could derive from the same biogenetic pathway. In order to confirm that the structure of barmumycin is actually that of E-16, we synthesized the latter and subsequently compared it to an authentic sample of the former. This began with selective silyl protection of the primary alcohol in the commercially available NBoc-trans-4-hydroxy-L-prolinol followed by oxidation of the secondary alcohol in the derivative 17, which afforded ketone 18 in 62% yield over two steps (Scheme 4 Comparison of spectroscopic data obtained for E-16 and barmumycin confirmed that the revised structure is indeed the structure of the natural product.
In summary, the previously unreported marine compound barmumycin was isolated, and its chemical formula was determined via mass spectrometry. Based on preliminary NMR data, barmumycin was initially assigned the structure of compound 1. To confirm this assignment, compound 1 was synthesized following two different strategies starting from an ortho-aminobenzoic ester: one based on reductive amination, and one based on N-alkylation, which was shorter and higher-yielding. However, comparison of the NMR spectra for 1 with those for isolated barmumycin showed dramatic differences. The structure of barmumycin was reassessed, and most probable option conceived was compound E-16, which was subsequently prepared (in five steps and 18% overall yield) for comparison with the natural compound. The spectroscopic data for E-16 fully coincided with that for barmumycin, thereby confirming that the two structures are equivalent. This work is a new example of the importance of total synthesis for structural characterization and confirmation of natural products 21 .
Experimental section
See Supporting Information for General Procedures.
Extraction and isolation of barmumycin
The culture broth (10 L) was separated by filtration into a mycelial cake and cultured filtrate (9 L). A 500 mL aliquot of the absorber resin XAD-1180 was added to the filtrate. Compound This quantity of barmumycin was treated with 0.5 mL of pyridine and 0. 170.6 (s). 
Methyl 2-[N-(3-(2,2-dimethyl-1,3-dioxolan-4-yl)-2-oxopropyl)trifluoroacetamido]-5-methoxybenzoate (9)
.
1-Bromo-3-(2,2-dimethyl-1,3-dioxolan-4-yl)propan-2-one (13

(S,E)-1-tert-Butoxycarbonyl-4-ethylidene-2-(trimethylsilyloxymethyl)pyrrolidine (E-19).
A 2M solution of LDA in THF (0.25 mL, 0.5 mmol) was added to a solution of 5- C-NMR are identical as described for the natural product in Table 2 
